Werewolf Therapeutics
HOWL
65 hedge funds and large institutions have $24.3M invested in Werewolf Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 70 → 65 (-5)
9% less capital invested
Capital invested by funds: $26.7M → $24.3M (-$2.36M)
11.49% less ownership
Funds ownership: 61.22% → 49.73% (-11%)
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
89% less call options, than puts
Call options by funds: $1K | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$552K |
| 2 |
Jane Street
New York
|
+$386K |
| 3 |
Renaissance Technologies
New York
|
+$260K |
| 4 |
Goldman Sachs
New York
|
+$119K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.17M |
| 2 |
BlackRock
New York
|
-$1.35M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.3M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$401K |
| 5 |
State Street
Boston,
Massachusetts
|
-$335K |
HOWL Hedge Fund Activity: Q2 2025 in Review
65 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2025, worth a combined $24.3M — down 8.8% from $26.7M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of HOWL and 17 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 15 added.
The largest buyer was RA Capital Management, adding an estimated $552K. The largest seller was PFM Health Sciences, cutting an estimated $2.17M.
- 65 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2025, down from 70 in Q1 2025.
- Funds reported $24.3M of Werewolf Therapeutics stock for Q2 2025, down 8.8% quarter-over-quarter.
- 17 funds opened new Werewolf Therapeutics positions in Q2 2025 and 22 closed out, a net change of -5 holders.
- The largest Werewolf Therapeutics buyer in Q2 2025 was RA Capital Management, an estimated $552K added.
- The largest Werewolf Therapeutics seller in Q2 2025 was PFM Health Sciences, an estimated $2.17M sold.
Based on aggregated 13F filings for Q2 2025.